News Release

Journal Article Cites HemoVoid™ in Proteomic Study of COPD

MONMOUTH JUNCTION, NJ, November 29, 2022 -- Biotech Support Group reports on a research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching erythrocyte proteins, in order to assess proteomic differences associated with COPD by LC-MS analysis.

The citation is:

Das, Sonu, et al. "A journey to unravel the pathophysiology of stable and exacerbated Chronic obstructive pulmonary disease through erythrocyte proteomics: A combined mass spectrometry/bioinformatics approach." (2022).

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disorder with high mortality. The present study, explores the novel and highly enriched protein networks differentially expressed in stable and exacerbated COPD variants to elucidate the disease pathophysiology. A label free relative quantification of erythrocyte cytosol proteome based on LC-MS/MS was performed on hemoglobin- depleted erythrocyte lysate samples of stable and exacerbated COPD, relative to healthy controls. To deplete Hemoglobin, the article states “HemoVoid™, a silica-based protein enrichment matrix from Biotech Support Group USA, was used to remove hemoglobin from erythrocyte lysate samples to unmask low abundance…proteins according to the manufacturer’s protocol.” 

The article describes the observation of five highly enriched protein clusters in stable and seven in exacerbated COPD. Such differentially expressed proteins brought to light the dysregulation of molecular events such as ERAD pathway, MAPK signaling, ciliogenesis, hypoxia, apoptosis and neutrophil migration, resulting in the chronic inflammatory response characteristic of COPD. The hemoglobin depleted erythrocyte cytosolic proteins which are unique to exacerbated COPD, such as kyphoscoliosis peptidase, sperm associated antigen-1, LINE 1 and calpastatin could help in differentiating stable and exacerbated COPD clinically.

“It’s very rewarding to see that for Hemoglobin removal, HemoVoid™ was an essential product to enrich the red blood cell proteome for this study. Without such an efficient enrichment of the low abundance proteome, the pathways and potential biomarkers associated with exacerbated COPD would not have been observed in the LC-MS proteomic analysis.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com

Keywords

Chronic obstructive pulmonary disease, COPD, Hemoglobin depletion, erythrocyte proteomics, Kyphoscoliosis peptidase, Sperm associated antigen-1, ERAD pathway, MAPK signaling, ciliary dysfunction, purine salvage, LC-MS, mass spectrometry